-
公开(公告)号:KR101579496B1
公开(公告)日:2015-12-23
申请号:KR1020140083249
申请日:2014-07-03
Applicant: 한국과학기술연구원
CPC classification number: A61K51/0455 , Y10S514/903
Abstract: 본발명은방사성표지된 [C]퀴놀린화합물이포함된방사성조성물에관한것이다. 본발명의 [C]퀴놀린화합물은 mGluR5에대하여특이적으로결합결합하는방사성리간드로유용하므로, mGluR5의과다발현으로유래된질환의진행또는완화를모니터링하기위한영상화제로유용하다.
Abstract translation: 本发明涉及包含放射性标记的喹啉化合物[^ 11C]的放射性组合物。 本发明的喹诺酮化合物[^ 11C]可用作与mGluR5特异性结合的放射性配体,可用作进行或缓解来自mGluR5的过表达的疾病的显像剂。
-
公开(公告)号:KR101418078B1
公开(公告)日:2014-07-10
申请号:KR1020130007540
申请日:2013-01-23
Applicant: 한국과학기술연구원
IPC: C07D215/12 , C07D401/06 , A61K31/47 , A61P25/00
CPC classification number: C07D215/06 , C07D215/20 , C07D401/06
Abstract: The present invention relates to a 2-(substituted ethynyl)quinoline derivative having activity as an mGluR5 antagonist and to a pharmaceutically acceptable salt of the same. The compound of the present invention can be used as a medicine to treat and prevent mGluR5 acceptor-mediated diseases, for example; Alzheimer′s, senile dementia, Parkinson′s disease, L-dopa-induced dyscinesia, Huntington′s chorea, amyotrophic lateral sclerosis, disseminated sclerosis, schizophrenia, anxiety disorders, dysthymia, neuropathic pains, drug dependence, fragile X syndrome, autism, migraine, and gastroesophageal reflux disease (GERD).
Abstract translation: 本发明涉及具有作为mGluR5拮抗剂的活性的2-(取代的乙炔基)喹啉衍生物及其药学上可接受的盐。 本发明的化合物可以用作治疗和预防mGluR5受体介导的疾病的药物; 老年痴呆症,老年痴呆症,帕金森病,左旋多巴诱发的运动障碍,亨廷顿氏舞蹈病,肌萎缩性侧索硬化,弥漫性硬化症,精神分裂症,焦虑障碍,心境恶劣,神经性疼痛,药物依赖,脆性X综合征,自闭症, 偏头痛和胃食管反流病(GERD)。
-